Lowdell Mark William 4

What Happened
Mark William Lowdell, Chief Scientific Officer of Inmune Bio, exercised 7,211 common stock purchase warrants on July 2, 2026, acquiring 7,211 shares at a reduced exercise price of $1.40 per share for a total of $10,095 (transaction code M). The filing also reports a related disposition labeled with transaction code X for the same 7,211 units at $0.13 per unit for $901 (reported as a derivative disposition).

Key Details

• Transaction date: 2026-07-02; Form 4 filed: 2026-07-07 (5 days after the transaction date).
• Acquired: 7,211 shares @ $1.40 = $10,095 (exercise of warrants) — code M.
• Disposed (related derivative entry): 7,211 units @ $0.13 = $901 — code X.
• Shares owned after the transaction: not disclosed in the excerpt of the filing provided.
• Footnote: The warrants were part of Inmune’s April 2024 warrants amended Dec 22, 2025. Per an inducement letter, Lowdell agreed to exercise 50% of his April 2024 warrants at a reduced $1.40 price in exchange for the company extending the maturity of the remaining 50% of those warrants to Dec 31, 2027.
• Filing timing: The Form 4 was submitted five days after the July 2 transaction (insider filings are typically required within two business days).

Context
This was an exercise of previously issued warrants (a purchase of shares), not a grant or a standard open-market buy. The footnote explains the exercise was part of a negotiated inducement to extend the maturity of the remaining warrants. The separate 'X' coded entry reports a related derivative disposition at a small per-unit amount; such X entries often reflect related derivative steps tied to the exercise or settlement but are reported separately on Form 4. The purchase is a direct acquisition of shares (a bullish signal in the sense of insider buying), while the X-coded entry reflects a related derivative transaction—avoid inferring broader intent from the derivative disposition alone.